A 12-week study on the new type 2 diabetes treatment omarigliptin is proving effective at reducing blood sugar levels in diabetic patients, according to research published in the journal Diabetes Care. The study is an extension of a longer-term safety and tolerability study of 25 mg dose of omarigliptin over 66 weeks. Researchers found that when patients taking omarigliptin were compared to patients taking metformin, adverse events remained similar, hypoglycemia was rare, and the drug was well tolerated. Merck & Co. has filed a new drug application for omarigliptin in Japan, with plans to file for approval in the United ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.